CTLA4 and non-small cell lung carcinoma: Combinations with CT have been found to provide clearly superior results compared to CT in first-line treatment in NSCLC, although the anti-PD-L1/anti-CTLA4 combination is an alternative to consider in certain subgroups of patients.